Browse > Article
http://dx.doi.org/10.5483/BMBRep.2015.48.8.076

Naturally occurring reoviruses for human cancer therapy  

Kim, Manbok (Department of Medical Science, Dankook University College of Medicine)
Publication Information
BMB Reports / v.48, no.8, 2015 , pp. 454-460 More about this Journal
Abstract
Naturally occurring reoviruses are live replication-proficient viruses that specifically infect human cancer cells while sparing their normal counterpart. Since the discovery of reoviruses in 1950s, they have shown various degrees of safety and efficacy in pre-clinical or clinical applications for human anti-cancer therapeutics. I have recently discovered that cellular tumor suppressor genes are also important in determining reoviral tropism. Carcinogenesis is a multi-step process involving the accumulation of both oncogene and tumor suppressor gene abnormalities. Reoviruses can exploit abnormal cellular tumor suppressor signaling for their oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ataxia telangiectasia mutated (ATM), and retinoblastoma associated (RB) are known to play important roles in genomic fidelity/maintenance. Thus, a tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to the accumulation of genetic defects which in turn could result in oncolytic reovirus susceptibility. This review outlines the discovery of oncolytic reovirus strains, recent progresses in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and reoviral oncotropism, and their clinical implications. Future directions in the utility of reovirus virotherapy is also proposed in this review. [BMB Reports 2015; 48(8): 454-460]
Keywords
Attenuated reovirus; Oncogene; Oncolytic virus; Reovirus; Tumor suppressor gene;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Ramig RF, Cross RK, and Fields BN (1977) Genome RNAs and polypeptides of reovirus serotypes 1, 2, and 3. J Virol 22, 726-733
2 Stanley NF, Dorman DC and Ponsford J (1953) Studies on the pathogenesis of a hitherto undescribed virus (hepato-encephalomyelitis) producing unusual symptoms in suckling mice. Aust J Exp Biol Med Sci 31, 147-159   DOI
3 Sabin AB. Reoviruses (1959) A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 130, 1387-1389   DOI
4 Stanley NF (1961) Relationship of Hepatoencephalomyelitis Virus and Reoviruses. letters to Nature 189, 687   DOI
5 Ramos-Alvarez M and Sabin AB (1954) Characteristics of poliomyelitis and other enteric viruses recovered in tissue culture from healthy American children. Proc Soc Exp Biol Med 87, 655-661   DOI
6 Stoeckel J and Hay JG (2006) Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutics. Curr Opin Mol Ther 8, 249-260
7 Ramos-Alvarez M and Sabin AB (1958) Enteropathogenic viruses and bacteria. Role in summer diarrheal diseases of infancy and early childhood. Jour Amer Med Ass'n 167, 147-156   DOI
8 Jackson GG, Muldoon BL and Cooper GS (1961) Reovirus type 1 as an etiologic agent of the common cold. Jour Clin Invest 40, 1051
9 Ramos-Alvarez M and Sabin AB (1956) Intestinal viral flora of healthy children demonstrable by monkey kidney tissue culture. Amer Jour Pub Health 46, 295-299   DOI
10 Rosen L, Evans HE and Spickard A (1963) Reovirus infections in human volunteers Am J Hyg 77, 29-37
11 Vidal L, Pandha HS, Yap TA et al (2008) A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14, 7127-7137   DOI
12 Kim M (2015) Replicating poxviruses for human cancer therapy. J Microbiol 53, 209-218   DOI
13 Roberts MS, Lorence RM, Groene WS and Bamat MK (2006) Naturally oncolytic viruses. Curr Opin Mol Ther 8, 314-321
14 Wang G, Barrett JW, Stanford M et al (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 103, 4640-4645   DOI
15 Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17, 3351-3362   DOI
16 Kim M, Williamson CT, Prudhomme J et al (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29, 3990-3996   DOI
17 Tyler KL (2001) Mammalian reoviruses, p. 1729-1745. In B.N. Fields, D.M. Knipe, and P.M. Howley (eds), Fields Virology, Lippincott-Raven, Philadelphia, USA
18 Harrington KJ, Karapanagiotou EM, Roulstone V et al (2010) Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16, 3067-3077   DOI
19 Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM (2014) Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 22, 1056-1062   DOI
20 Le Boeuf F, Diallo JS, McCart JA et al (2010) Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18, 888-895   DOI
21 Alkassar M, Gärtner B, Roemer K et al (2011) The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J Neurooncol 104, 715-727   DOI
22 Forsyth P, Roldán G, George D et al (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16, 627-632   DOI
23 Karapanagiotou EM, Roulstone V, Twigger K et al (2012) Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18, 2080-2089   DOI
24 Galanis E, Markovic SN, Suman VJ et al (2012) Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 20, 1998-2003   DOI
25 Morris DG, Feng X, DiFrancesco LM et al (2013) REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 31, 696-706   DOI
26 Minuk GY, Paul RW and Lee PW (1985) The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 16, 55-60   DOI
27 Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K and Kelly JK (1987) Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 5, 8-13   DOI
28 Kim M, Egan C, Alain T et al (2007) Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26, 4124-4134   DOI
29 Alain T, Kim M, Johnston RN et al (2006) The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer 95, 1020-1027   DOI
30 Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM and Demetrick DJ (2004) Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anticancer biotherapeutics. Cancer Biol Ther 3, 734-738   DOI
31 Kim M, Garant KA, zur Nieden NI et al (2011) Attenuated reovirus displays oncolysis with reduced host toxicity. Br J Cancer 104, 290-299   DOI
32 Kim M and Johnston RN (2014) Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy. Chinese patent No.: 200980126543.5 Date of Patent grant: July 30, 2014
33 Lolkema MP, Arkenau HT, Harrington K et al (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17, 581-588   DOI
34 Comins C, Spicer J, Protheroe A et al (2010) REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16, 5564-5572   DOI
35 Alloussi SH, Alkassar M, Urbschat S, Graf N and Gärtner B (2011) All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma. Oncol Rep 26, 645-649
36 Coschi CH and Dick FA (2012) Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol Life Sci 69, 2009-2024   DOI
37 Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726   DOI
38 Bennette JG (1960) Isolation of a Non-pathogenic Tumour-destroying Virus from Mouse Ascites. Nature 187, 72-73   DOI
39 Nelson JB and Tarnowski GS (1960) An Oncolytic Virus recovered from Swiss Mice during Passage of an Ascites Tumour. Nature 188, 866-867   DOI
40 Bennette JG, Bush PV and Steele RD (1967) Characteristics of a newborn runt disease induced by neonatal infection with an oncolytic strain of reovirus type 3 (REO3MH). I. Pathological investigations in rats and mice. Br J Exp Pathol 48, 251-266
41 Hashiro G, Loh PC and Yau JT (1977) The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54, 307-315   DOI
42 Duncan MR, Stanish SM and Cox DC (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28, 444-449
43 Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17, 3351-3362   DOI
44 Coffey MC, Strong JE, Forsyth PA and Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334   DOI
45 Kim M, Chung YH and Johnston RN (2007) Reovirus and tumor oncolysis. J Microbiol 45, 187-192
46 Kuttler F and Mai S (2006) c-Myc, Genomic Instability and Disease. Genome Dyn 1, 171-190
47 Prochownik EV and Li Y (2007) The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 6, 1024-1029   DOI
48 Prochownik EV (2008) c-Myc: linking transformation and genomic instability. Curr Mol Med 8, 446-458   DOI